Targeting inhibitors of apoptosis proteins (IAPs) for new breast cancer therapeutics.
Apoptosis resistance is a hallmark of human cancer. Research in the last two decades has identified key regulators of apoptosis, including inhibitor of apoptosis proteins (IAPs). These critical apoptosis regulators have been targeted for the development of new cancer therapeutics. In this article, we will discuss three members of IAP proteins, namely XIAP, cIAP1 and cIAP2, as cancer therapeutic targets and the progress made in developing new cancer therapeutic agents to target these IAP proteins.
Comprehensive Cancer Center and Departments of Internal Medicine, Pharmacology and Medicinal Chemistry, University of Michigan, Ann Arbor, MI 48109, USA. shaomeng@umich.edu
Shaomeng
S
Wang
Longchuan
L
Bai
Jianfeng
J
Lu
Liu
L
Liu
Chao-Yie
CY
Yang
Haiying
H
Sun
D000970:Antineoplastic Agents / Q000627:therapeutic use*; D001943:Breast Neoplasms / Q000188:drug therapy* / Q000378:metabolism; D005260:Female; D006801:Humans; D051034:Inhibitor of Apoptosis Proteins / Q000037:antagonists & inhibitors*; D058990:Molecular Targeted Therapy
D000970:Antineoplastic Agents; D051034:Inhibitor of Apoptosis Proteins